Departments View all

3,546
Total Impact Points
4
Members

Recent Publications View all

  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan. The management of castration-resistant prostate cancer is complex and has opened new fields of research during the last decade leading to an improved understanding of the biology of the disease and the development of new therapies. Most advanced tumors resistant to therapy still maintain the androgen receptor-pathway, which plays a central role for survival and growth of most castration-resistant prostate cancers. Many mechanisms induce the emergence of the castration resistant phenotype through this pathway. However some non-related AR pathways like neuroendocrine cells or overexpression of anti-apoptotic proteins like Hsp27 are described to be involved in CRPC progression. More recently, loss of expression of tumor suppressor gene, post-transcriptional modification using miRNA, epigenetic alterations, alternatif splicing and gene fusion became also hallmarks of castration-resistant prostate cancer. This review presents an up-to-date overview of the androgen receptor-related mechanisms as well as the latest evidence of the non-AR-related mechanisms underlying castration-resistant prostate cancer progression. Copyright © 2015 Elsevier Ltd. All rights reserved.
    No preview · Article · May 2015 · Cancer Treatment Reviews
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: - Copyright © 2014, Ferrata Storti Foundation.
    Full-text · Article · Dec 2014 · Haematologica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with relapsed or refractory Hodgkin lymphoma (RR-HL) have poor outcomes. Brentuximab vedotin (BV), an antibody-drug conjugate comprising an anti-CD30 antibody conjugated to the potent anti-microtubule agent, monomethyl auristatin E, induces high tumour responses with moderate adverse effects. In a retrospective study, we describe objective response rates and subsequent allogeneic stem cell transplantation (allo-SCT) in patients with RR-HL treated by BV in a named patient program in two French institutions. Twenty-four adult patients with histologically proven CD30(+) RR-HL treated with BV were included from July 2009 to November 2012. Response to BV treatment was evaluated after four cycles. Eleven patients were in complete response (45.8%), while five patients were in partial response (20.8%), with an overall response rate of 66.6%. Eight patients failed to respond to BV (33.3%). All of the responding patients could receive consolidation treatment after BV: three patients underwent autologous stem cell transplantation (auto-SCT), three patients received a tandem auto-SCT/allo-SCT, nine patients received allo-SCT and one patient was treated with donor lymphocyte infusion. We found no treatment-related mortality at day 100 among the 12 patients who underwent BV following by allogeneic transplantation. With a median follow-up of 20 months (range 10.5-43.2), none of them relapsed or died. BV followed by allo-SCT represents an effective salvage regimen in patients with RR-HL. Copyright © 2013 John Wiley & Sons, Ltd.
    No preview · Article · Dec 2014 · Hematological Oncology

Information

  • Address
    Marseille, France
Information provided on this web page is aggregated encyclopedic and bibliographical information relating to the named institution. Information provided is not approved by the institution itself. The institution’s logo (and/or other graphical identification, such as a coat of arms) is used only to identify the institution in a nominal way. Under certain jurisdictions it may be property of the institution.

45 Members View all

View all

Top publications last week by reads

 
Nature Reviews Immunology 03/2012; 12(4):239-52. DOI:10.1038/nri3174
12 Reads
 
Oncologie 12/2015; 17(11-12). DOI:10.1007/s10269-015-2557-5
12 Reads

Top Collaborating Institutions

Collaborations

This map visualizes which other institutions researchers from Institut Paoli Calmettes have collaborated with.

Rg score distribution

See how the RG Scores of researchers from Institut Paoli Calmettes are distributed.